The Board of GeNeuro

Jesùs Martin-Garcia

Jesus holds a Bs in Business Administration, a Ms in Law from the University of Geneva and a MBA from Harvard Business School. Jesùs is a highly successful entrepreneur who has created, invested in and developed several technology-focused start-ups such as VTX, Silverwire and LeShop, Switzerland’s largest e-commerce company that he co-founded in 1997. Jesus began his career at McKinsey & Co where he managed teams in the pharma and consumer goods industries. He is a director of Eclosion. Jesus is the Chairman of the Board of GeNeuro.

 

Dr. Benoît Dubuis

Benoît is a chemical engineer from the Swiss Federal Institute of Technology of Lausanne (EPFL) and holds a PhD in Biotechnology from the Swiss Federal Institute of Technology of Zurich (ETHZ) . He occupied different management positions in pharmaceutical companies, including Ciba-Geigy, Novartis and Lonza. He joined the EPFL in 2000, established the School of Life Sciences and served as its first Dean. He also founded Excellgene SA and is the President of the BioAlps association. He is a director of Eclosion.

 

Jean Deleforge

Jean is the Corporate Vice President of Molecular Unit at bioMérieux since 2009. From 2000 to 2008, Jean has worked at bioMérieux where he successively held positions at Portfolio Management, Business Development and BioMarker Research. He is a Board member of several Biotech companies involved in in vitro diagnostic or therapeutics. He held Senior Management positions in Preclinical & Clinical development at Vetoquinol and Merial. He is a Doctor in Veterinary Medicine from Maisons-Alfort and holds a Master of Strategic Management of Innovation from HEC- Polytechnique school in Paris.

 
 

Michel Dubois

Michel is a Director at GeNeuro SA, President of GeNeuro Innovation SAS. He is also a Director at Stallergénes and at the Hospital St Luc St Joseph in Lyon. Michel is Honorary Consul of Canada in Lyon. He was the Director General of Institut Mérieux and a consultant at McKinsey and Arthur Andersen.

 

Dr. François Curtin

François graduated with an MD from Geneva Medical School and obtained a Master in Philosophy in Medical Statistics from the London School of Hygiene and Tropical Medicine. He has a MBA from Warwick Business School.  After several years in academia, he joined Swissmedic, the Swiss Medicine Agency where he was responsible for the registration and market surveillance of neuropsychiatric drugs. Then, he joined Serono SA, then Merck Serono SA, where he worked in clinical and business development. Since 2009, François is the CEO of GeNeuro.

 

Dr. Hervé Perron  

Hervé has a PhD in Virology and a Professoral Thesis in Neuroimmunology. He is the author of over 120 peer-reviewed publications and patents and is referee for various scientific journals. He was Research Director of R&D within bioMérieux for the development of in vitro diagnostics in the domain of Neurological diseases. Hervé was Scientific Director of bioMérieux STELHYS, a spin-off dedicated to the evaluation of developments of upstream research projects. Hervé is a co-founder and Chief Scientific Officer of GeNeuro and the general manager of GeNeuro-Innovation.